1Murphy S, Peterson P,Iland H, et al. Experience of the Polycythemia Vera StudyGroup with essential thrombocythemia：a final report on diagnostic criteria,survival,andleukemic transition by treatment .Semin Hematol,1997,34：29～39
2Basses C, Cervantes F, Pereira A, et al. Major vascular complications in essentialthrombocythemia：a study of the predictive factors in a series of 148 patients.Leukemia,1999,13：150～154
3Sterkers Y, Preudhomme C,Lai JL, et al. Acute myeloid leukemia and myelodysplasticsyndromes following essential thrombocythaemia treated with hydroxyura：high proportionof cases with 17p deletion. Blood,1998,91：616～622
4Barbui T, Finazzi G, Dupuy E, et al. Treatment strategies in essentialthrombocythemia：a critical appraisal of various experiences in different centers.Leukemia and Lymphoma,1996,22(Suppl 1)：149～160
收稿 1999-03-30
修回 1999-09-10
8Zauli G,Vitale M,Falcieri E,et al.In vitro senescence and apoptotic cell death of human megakaryocytes.Blood,1997,90:2234-2243.
9Wagner KU,Claudio E,Rucker EB 3rd,et al.Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly.Development,2000,127:4949-4958.
10Kaluzhny Y,Yu G,Sun S,et al.Bcl-xL overexpression in megakaryocytes leads to impaired platelet fragmentation.Blood,2002,100:1670 -1678.
